Treatment of Libman-Sacks endocarditis by combination of warfarin and immunosuppressive therapy
TURK KARDIYOLOJI DERNEGI ARSIVI-ARCHIVES OF THE TURKISH SOCIETY OF CARDIOLOGY, cilt.47, sa.8, ss.687-690, 2019 (ESCI, Scopus, TRDizin)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 47 Sayı: 8
- Basım Tarihi: 2019
- Doi Numarası: 10.5543/tkda.2019.29213
- Dergi Adı: TURK KARDIYOLOJI DERNEGI ARSIVI-ARCHIVES OF THE TURKISH SOCIETY OF CARDIOLOGY
- Derginin Tarandığı İndeksler: Emerging Sources Citation Index (ESCI), Scopus, TR DİZİN (ULAKBİM)
- Sayfa Sayıları: ss.687-690
- Anahtar Kelimeler: Antiphospholipid syndrome, immunosuppressive therapy, Libman-Sacks endocarditis, systemic lupus erythematosus, warfarin, NONBACTERIAL THROMBOTIC ENDOCARDITIS, ANTIPHOSPHOLIPID SYNDROME, FOLLOW-UP, MANAGEMENT, DIAGNOSIS
- İstanbul Üniversitesi Adresli: Evet
Özet
Antiphospholipid syndrome (APS) is a clinical disorder that creates an increased risk of arterial or venous thrombotic events or pregnancy-associated complications and includes the presence of autoantibodies against negatively charged phospholipids. This syndrome is often associated with systemic autoimmune diseases, such as systemic lupus erythematosus (SLE). Libman-Sacks endocarditis is a form of non-bacterial thrombotic endocarditis and is infrequently seen in APS. There are few data documenting the echocardiographic response of APS valve disease to medical treatment. This is an unusual case of a young female patient with SLE and APS who had chorea and non-bacterial thrombotic aortic valve endocarditis. Echocardiography revealed that the vegetation had receded after a combination of warfarin and immunosuppressive therapy.